Speaker Profile
                                                                        Biography
                                                                        Judy Faulkner, founder and CEO of Epic Systems, has significantly impacted precision medicine by pioneering the integration of genomic data into electronic health records, notably through Epics Aura platform, which enables tailored treatment strategies based on individual genetic profiles. Under her leadership, the Cosmos initiative has facilitated the aggregation of extensive de-identified patient data, substantially advancing clinical research and informed medical decision-making. Additionally, by embedding advanced AI technologies into Epic's systems, she has streamlined clinical workflows, aiding healthcare providers in documentation and patient communication. Epics extensive global presence, managing hundreds of millions of patient records, reflects Faulkner's profound influence on the healthcare landscape, further highlighted by her philanthropic commitment to reducing health disparities and improving healthcare accessibility.
                                                                    
                                                                    
                                                                    
                                                                    
Session Abstract – PMWC 2026 Silicon Valley
                                                                        
                                                                        Track Chair: Catriona Jamieson, UCSD
PMWC Award Ceremony Honorees
• Judy Faulkner, Epic
• Svetlana Mojsov, The Rockefeller University (GLP-1)
• Alexis C. Komor, UCSD
Opening Talk
• Catriona Jamieson, UC San Diego
GLP-1: From Hormone Discovery to a Global Therapeutic Revolution
• Svetlana Mojsov, The Rockefeller University
What’s Next at Epic?
• Peter DeVault, Epic
Modified mRNA, siRNA, ASOs
• Chair: Alexis C. Komor, UC San Diego
• Niren Murthy, UC Berkeley
• Gene Yeo, UC San Diego
• Reuben Harris, UT Health San Antonio
Stem Cell–Targeted Therapeutics: Small Molecules & Biologics
• Chair: Catriona Jamieson, UC San Diego
• Irving L. Weissman, Stanford
In Vivo Gene Therapies
• Chair: Gene Yeo, UC San Diego
• Mark A. Kay, Stanford
• David Schaffer, UC Berkeley
Diagnostics, Prognostics, and Patient Stratification
• Chair: Ezra Cohen, Tempus
• Eitan Ruppin, NIH
• Danielle Hamel, Tempus
• David Ledbetter, Florida State University
• Ludmil Alexandrov, UC San Diego
Closing
• Catriona Jamieson, UC San Diego
                                                                    





 
								 
                                                                         
     
                                                                         
															 
															